Hepatitis B Virus Persistence after Recovery from Acute Viral Hepatitis

Thomas I. Michalak, Claudio Pasquinelli, Stephane Guilhot, and Francis V. Chisari
Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037

Abstract
Contrary to current opinion, the disappearance of hepatitis B surface antigen (HBsAg) from the serum, the development of anti-HBs antibodies, and normalization of liver function may not reflect complete virological recovery from acute hepatitis B virus (HBV) infection. By using the polymerase chain reaction (PCR), in the current study we demonstrate long-term persistence of HBV DNA in the serum and peripheral blood mononuclear cells (PBMC) of four patients for up to 70 mo after complete clinical, biochemical, and serological recovery from acute viral hepatitis. Serum HBV DNA reactivity co-sedimented with HBsAg in sucrose gradients, and it displayed the size and density characteristics of naked core particles and intact HBV virions, primarily contained within circulating immune complexes in these anti-HBs antibody-positive sera. HBV DNA was also present in PBMC in late convalescent samples from all four patients, and HBV RNA was detected in late convalescent phase PBMC in two of these patients. These results suggest that HBV DNA, and possibly HBV virions, can be present in the serum, and that the viral genome can persist in a transcriptionally active form in PBMC for >5 yr after complete clinical and serological recovery from acute viral hepatitis. (J. Clin. Invest. 1994. 93:230–239) Key words: hepatitis B • hepatitis B virus • immunity • liver diseases • polymerase chain reaction • viral DNA

Introduction
Seroconversion to hepatitis B surface antigen (HBsAg)\(^1\) negativity with the appearance of antibodies to HBsAg (anti-HBs) and normalization of liver function have been generally accepted as evidence of viral clearance during acute hepatitis B (1). However, since hepatitis B virus (HBV) DNA sequences may persist in the serum and in liver patients with chronic hepatitis long after disappearance of HBsAg and appearance of anti-HBs (2–5) it is possible that viral DNA may not be completely eradicated at the time of clinical, biochemical, and serological recovery from acute HBV infection. This is supported by the demonstration of woodchuck hepatitis virus DNA in livers and peripheral blood lymphocytes of apparently healthy woodchucks after serological and biochemical recovery from acute hepatitis (6). In addition, there is growing evidence that the HBV genome persists in serum and liver despite the clearance of serum HBsAg and anti-HBs seroconversion during antiviral therapy for chronic hepatitis B (5, 7–10). In some of these patients, HBV DNA sequences were detected in PBMC several years after the disappearance of HBsAg from serum (11).

To determine whether HBV might persist in the circulation after complete serologic and clinical recovery from acute hepatitis B, we examined serum and PBMC of healthy individuals with a history of self-limited acute hepatitis B (SL-AH) infection for HBV DNA using the PCR. We have found HBV DNA sequences in the serum and PBMC for up to 70 mo after complete resolution of an acute episode of hepatitis B. Biochemical, biophysical, and immunochemical analysis suggests that the serum HBV DNA sequences may be present within intact virions in circulating immune complexes, and that the HBV DNA is transcriptionally active in PBMC long after serological, biochemical, and clinical recovery from acute viral hepatitis.

Methods
Sera and PBMC: Serum samples were collected sequentially from four individuals (three males and one female; mean age 26 yr). The first sample was drawn during an acute episode of typical type B hepatitis when serum alanine aminotransferase activity averaged 1,648±853 IU/L. Subsequent samples were obtained at various times (between 7 and 70 mo) after complete clinical, biochemical, and serological recovery from the disease (Table I). At least three serum samples were obtained from each individual. Three of the patients (cases 2, 3, and 4) developed anti-HBs and remained antibody positive for 3–5 yr of follow-up. One patient (case 1) cleared HBsAg but did not yet developed anti-HBs when she was lost to follow-up 7 mo after clinical resolution of her liver disease. PBMC harvested at the end of the observation period were available for examination in three patients. In the remaining patient (case 3), PBMC were obtained 7 mo after disease onset, at the time when anti-HBs was already detectable in the circulation. All individuals investigated were a part of the patient cohort participating in a long-standing study on the cellular immune responses to HBV and they were only patients with self-limited hepatitis B which were followed up for longer than 6 mo after complete clinical, biochemical, and serological recovery from hepatitis.

Serum samples were also collected from a patient with extremely severe acute (fulminant) hepatitis with coma, who spontaneously recovered while awaiting a liver transplant (case 5; Table I). Control sera and PBMC were obtained from two HBV DNA-positive patients with histologically proven chronic active hepatitis B (CAHB) and from three controls with no clinical or serological evidence of HBV infection.

Seroassays and slot-blot hybridization. HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc of IgM class were detected by conventional solid-phase assays using Ausria II, Ausab EIA, Abbott HBe (rDNA), and Corab M, respectively (Abbott Laboratories, North Chi...
The influence of sample was used with 70% of incubated at (10 mM corresponding site of pBR322 HBV (ayw subtype) cloned (12). Although serum was dissolved in TE buffer. The assay was determined using 10-fold serial dilutions of plasmid pFC80 that contains four complete sequences of HBV (ayw subtype) cloned as a head-to-tail tetramer into the EcoRI site of pBR322 (12). The assay sensitivity was 160 pg HBV DNA/ml, corresponding to a level of 10⁷ genomes/ml.

Preparation of serum samples for HBV DNA detection. Under most circumstances, 50 μl of serum were supplemented with 50 μl of TE buffer (10 mM Tris-HCl, pH 8.0, and 1 mM EDTA, pH 8.0) and incubated at 42°C for 3 h with proteinase K (50 μg/reaction) in 200 μl of lysis buffer containing 10 mM Tris-HCl, pH 8.0, 10 mM NaCl, 1 mM EDTA, pH 8.0, and 0.5% SDS.

DNA was extracted by the phenol-chloroform method, precipitated with sodium acetate-ethanol, washed with 70% ethanol, and dissolved in 20 μl of TE buffer. 10 μl of DNA sample was used for direct PCR amplification.

Although serum was used as the source of DNA in this study, the influence of different anticoagulants on the detectability of HBV DNA was assessed to determine if plasma samples could also be analyzed for HBV DNA by PCR. For this purpose, blood samples (~7 ml each) from the same HBsAg-positive individual with chronic hepatitis type B were collected using vacutainers with no additives (red tops) or containing sodium heparin (green tops), EDTA (lavender tops), and acid citrate dextrose (ACD; yellow tops) (Becton Dickinson, & Co., Rutherford, NJ). DNA was isolated from 50 μl of the resulting serum or plasma as described above.

To differentiate free HBV DNA molecules from virions or HBV core particles, selected serum samples were examined for HBV DNA content before and after extensive digestion with DNAAse. For DNAAse digestion, 50 μl of serum was supplemented with 30 μl of deionized water, 10 μl of DNAAse digestion buffer (500 mM Tris-HCl, pH 7.6, and 100 mM MgCl₂) and 10 μl of DNAAse solution (1 mg/ml; deoxyribonuclease I; Sigma Chemical Co., St. Louis, MO) and incubated at 37°C for 1 h. Each sample was digested three times to exclude the possibility of carryover of any free HBV DNA. At the end of the first and second incubation, 10 μl of the reaction mixture was re-

---

**Table I. Clinical and Laboratory Characteristics and HBV DNA Detection in Individuals Convalescent from Acute Hepatitis B**

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Sex (F/M)</th>
<th>Age (yr)</th>
<th>Clinical diagnosis</th>
<th>Time after disease onset (mo)</th>
<th>ALT (IU/liter)</th>
<th>HBsAg</th>
<th>anti-HBc</th>
<th>anti-HBe</th>
<th>Slot-blot hybridization</th>
<th>PCR-EB agarose</th>
<th>PCR-Southern hybridization</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>22</td>
<td>SL-AH</td>
<td>0.5</td>
<td>1638</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1</td>
<td>M</td>
<td>35</td>
<td>SL-AH</td>
<td>0.5</td>
<td>2355</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>M</td>
<td>27</td>
<td>SL-AH</td>
<td>0.5</td>
<td>450</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>27</td>
<td>SL-AH</td>
<td>0.5</td>
<td>2148</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>23</td>
<td>SL-AH</td>
<td>0.5</td>
<td>2160</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>31</td>
<td>CAHB</td>
<td>n.a.</td>
<td>120</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>39</td>
<td>CAHB</td>
<td>n.a.</td>
<td>106</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>28</td>
<td>Control</td>
<td>n.a.</td>
<td>27</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>26</td>
<td>Control</td>
<td>n.a.</td>
<td>12</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>33</td>
<td>Control</td>
<td>n.a.</td>
<td>20</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

SL-FH, self-limited fulminant hepatitis B; n.t., not tested; n.a., not applicable.

* Evaluated by Austria II (Abbott Laboratories). † Evaluated by Ausab EIA (Abbott Laboratories). ‡ Approximate sensitivity 10⁷ genome equivalents/ml. § Amplified by direct or nested PCR with HBV core primers and analyzed in 0.9% agarose with EB (sensitivity of direct and nested PCR 10⁻² and 10⁻³ genome equivalents/ml, respectively). †† Hybridization to HBC INT probe (approximate sensitivity for detection of direct and nested PCR products 10⁻³ and between 10⁻² and 10⁻³ genome equivalents/ml, respectively. ** Positive for anti-HBc IgM Corab M (Abbott Laboratories). ‡‡ Positive for anti-HBe by Abbott HBs (rDNA) assay (Abbott Laboratories).

---

*Hepatitis B Virus Persistence after Recovery from Acute Viral Hepatitis* 231
moved and 10 μl of fresh DNase solution was added. After the third incubation, each sample was treated with proteinase K, and DNA was extracted as described above. After phenol-chloroform extraction and precipitation with ethanol, DNA was dissolved in 20 μl of TE buffer and a 10-μl aliquot was analyzed by PCR. Results were compared with similarly treated HBsAg-positive serum from patients with chronic hepatitis, and with plasmid DNA containing the complete HBV genome.

**Determination of sedimentation velocity and buoyant density of particles carrying HBV DNA.** One hundred μl of late convalescent sera from cases 2, 3, and 4 were sedimented through 4 ml of 15% (wt/vol) sucrose in TN buffer (10 mM Tris-HCl, pH 8.0, and 140 mM NaCl) onto a 0.5-ml 60% sucrose cushion. Results were compared with two preparations of purified Dane particles (designated as D.J. and T.R.: generously provided by Dr. J. L. Gerin, Georgetown University, Rockville, MD), and a sample of recombinant plasmid pFC80 containing cloned HBV genome digested with restriction enzymes Sau3AI that were sedimented as controls. All tubes were centrifuged for 4 h at 40,000 rpm at 5°C in an SW60 rotor (Beckman Instruments, Inc., Palo Alto, CA). Fractions of 330 μl were collected from the bottom of each tube and sucrose density was determined in a refractometer. From each fraction, a 50-μl sample was boiled for 5 min in a water bath and assayed for HBV DNA by PCR. 200-μl samples of the fractions were also tested for HBsAg by Austria II kit (Abbott Laboratories). S/N values were calculated according to the procedure proposed by the manufacturer using relevant sucrose fractions of normal human serum as negative controls.

To determine the density of the serum HBV DNA, 200 μl of late convalescent sera were collected from cases 2, 3, and 4, control sera from HBV DNA-positive patients with CAHB, and a sample of Sau3AI digested plasmid DNA were layered onto 4.5 ml of continuous gradients of 1.1–1.7 g/cm³ CaCl2 in TE buffer. After centrifugation for 16 h at 40,000 rpm at 5°C in an SW60 rotor, 330-μl fractions were collected from the bottom of the tubes. 50-μl samples of those fractions were boiled for 5 min and tested for HBV DNA by PCR after ascertaining that cesium chloride did not adversely influence HBV DNA detection.

**Extraction of DNA and RNA from PBMC.** PBMC (≈ 2 × 10⁷ cells) isolated on Ficoll-Histopaque density gradients from heparinized blood were cryopreserved in 90% FCS and 10% DMSO and stored in liquid nitrogen until use. PBMC were thawed on ice and washed three times by centrifugation at 700 g for 8 min with a total of 45 ml of HBSS. The final cell wash was saved as a control for contamination of the PBMC with HBV DNA derived from blood or damaged cells. In complementary experiments, washed PBMC were suspended in 900 μl of HBSS containing 100 μl of 10× DNase digestion buffer and DNAse (100 μg/reaction), incubated at 37°C for 1 h, then supplemented with 10 μl of 100 mM CaCl2 and digested with trypsin (100 μg/reaction; type II; Sigma) for 30 min on ice. The resulting cells were washed with HBSS.

DNA isolation was performed as previously described (13). 50 μl of the isolated DNA was analyzed by PCR in parallel with 50-μl samples of the final PBMC wash. Total RNA was extracted from PBMC harvested at 39 and 70 mo from cases 2 and 4, respectively. The cells were homogenized and solubilized according to the acid guanidinium thiocyanate-phenol-chloroform method (14). The final RNA was treated with RNAase-free DNase I (2 U/reaction) (Promega Corp., Madison, WI) for 30 min at 37°C and then with RNAase H (1.5 U/reaction) (Bethesda Research Laboratories, Gaithersburg, MD) for 30 min at 37°C to eliminate possible viral RNA/DNA hybrids resistant to DNase digestion (15, 16). The enzymes were subsequently inactivated by incubation at 95°C for 5 min and the RNA stored at −70°C.

**PCR.** Two pairs of oligonucleotide primers specific for the HBV core gene and representing sequences conserved among HBV subtypes and an oligonucleotide probe homologous with the fragment internal to these primers were synthesized on a model 308B DNA synthesizer (Applied Biosystems, Inc., Foster City, CA). For control amplifications, external and nested primer pairs specific for the ampicillin resistance (AMP) gene of plasmid vectors commonly used in our laboratory and a single-stranded probe internal to these primers (AMP INT) were designed and synthesized. In addition, a primer pair specific for pre-S region (PSU-NSU) was used in selected studies. The characteristics of these oligonucleotides are provided in Table II.

DNA samples derived from sera (10 μl) or PBMC (~1 μg) were amplified in a 100-μl reaction volume in a programmable thermal cycler (TwinBlock System, Ericomp, Inc., San Diego, CA). The reaction mixture was prepared using GeneAmp reagents (Perkin-Elmer Cetus, Norwalk, CT) and a procedure proposed by the manufacturer. For amplification with the POC-COR primer pair (Table II), the samples were initially denatured at 93°C for 5 min, cooled to 52°C for 2 min to anneal the primers to the template DNA, and incubated at 70°C for 3 min to allow elongation. Subsequently, the amplification was carried out for 30 cycles. The last cycle was followed by a 3-min elongation step at 70°C. For the second round of amplification, 10 μl of the mixture resulting from the direct reaction was amplified with the PCN-NCO pair (Table II) using the same temperature program as that for the direct PCR.

Semiquantitative estimation of the level of HBV DNA in tested samples was done by amplifying 10-fold serial dilutions of the extracted DNA with the HBV core primers with subsequent detection of PCR products by Southern-blot hybridization to HBC INT probe (Table II). The levels of sensitivity of direct and nested PCRs were determined using 10-fold serial dilutions of cloned HBV genome in normal human serum or TE buffer, followed by hybridization detection of the amplified DNA products. This monitoring revealed that the sensitivity of the direct and nested PCRs employing the HBV core primers was 10⁻¹ and 10⁻² pg HBV DNA/ml, respectively (corresponding to ~10⁷ and between 10⁸ and 10⁹ genome equivalents/ml). The nested PCR amplification with AMP primers, coupled with hybridization analysis, could detect ~10⁻³ pg of pBR322 DNA/ml (equivalent to about 10-100 copies/ml).

Amplifications with primers specific for the HBV pre-S region and AMP gene were carried out for 40 cycles. The reaction mixture was heated to 94°C for 1 min, cooled to 58°C for 1 min, and then heated to 72°C for 1 min. Final elongation was done at 72°C for 5 min. The sensitivity of direct PCR using the HBV pre-S primers and ethidium bromide (EB)-agarose detection was ~10⁻² pg HBV DNA/ml (equivalent to about 10⁴ copies/ml).

To eliminate sources of DNA contamination, rigorous precautions were taken. All sera and PBMC samples were divided into small aliquots under sterile conditions in a laminar flow hood using disposable plasticware, before bringing them to the laboratory where they were handled separately from PCR products, bacterial plasmids, and other possible sources of HBV DNA contamination. Each sample was analyzed by PCR at least twice. In the cases of positive HBV DNA identification, DNA isolated from a newly opened aliquot of the same serum or PBMC sample was amplified to confirm the positive result. All amplifications were performed in parallel with relevant negative and positive controls which consisted of DNA derived from the sera and/or PBMC of healthy individuals and HBV-positive patients. Positive controls also included amplification of recombinant HBV DNA of the ayw subtype derived from plasmid pFC80. Contamination controls consisted of water added to the PCR mixture instead of DNA. All reagents and buffers used during DNA isolation and PCR amplification were periodically assayed for the presence of viral DNA contamination. To further confirm validity of HBV DNA identification, samples positive for HBV DNA were subjected to nested PCR amplification using primers specific for plasmid AMP gene (Table II). In addition, since the laboratory plasmids carry HBV ayw genomes only, amplification of the HBV DNA positive samples with primers specific for the pre-S region was performed to help verify the authenticity of the detected DNA by assessing divergence in the molecular size between the ad and ay subtypes of the virus.

Reverse transcriptase PCR. Approximately 1 μg of RNA derived from each PBMC preparation was used for CDNA synthesis. The reaction was performed using CDNA Synthesis System Plus (Amersham
**Table II. Sequence and Location of Oligonucleotide Primers and Probes**

<table>
<thead>
<tr>
<th>Sequence</th>
<th>Position</th>
<th>Expected size of target sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBV C-ORF specific External primers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCO (sense)</td>
<td>5'-CTGGGAGGAGTTGGGGGA</td>
<td>1732–1750*</td>
</tr>
<tr>
<td>COR (antisense)</td>
<td>5'-CTAACATTGAGATCCCGA</td>
<td>2454–2436*</td>
</tr>
<tr>
<td>Nested primers:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCN (sense)</td>
<td>5'-CTG TAGCATAAATGTT</td>
<td>1783–1800*</td>
</tr>
<tr>
<td>NCO (antisense)</td>
<td>5'-TCCGGAAGTGGTTGATA</td>
<td>2336–2321*</td>
</tr>
<tr>
<td>Probe:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HBC INT (sense)</td>
<td>5'-CCCTCACATACAGCAGCAGGCAA</td>
<td>2050–2073*</td>
</tr>
</tbody>
</table>

| HBV S-ORF specific Primers: | | |
| PSU (sense) | 5'-GGGTCAATATTTCTGGGA | 2816–2835* |
| NSU (antisense) | 5'-GTTCTAGGAATCCTGATG | 187–170* |

| Plasmid AMP* gene specific External primers | | |
| PPAC (sense) | 5'-CTCAGCGATCTGTCATTTGTCGA | 3324–3348* |
| XENQ (antisense) | 5'-GCCCGGAAGAAGCTTTTCCAATGAG | 3979–3952* |
| Nested primers | | |
| PPPA (sense) | 5'-ACTAGCAAGGGGGAGGCTTACACATCG | 3382–3408* |
| XXMN (antisense) | 5'-ATCCTCTGTTGACGCCCCGAAGCAG | 3918–3882* |
| Probe | | |
| AMP INT (sense) | 5'-CGTTTGGTGATGGCTTCATTCAC | 3635–3656* |

* Numbers denote the position of the sequence in HBV ayw (39), with the exception of position 2061 in HBC INT probe were threonine (T) was replaced with alanine (A), since this last nucleotide is more frequently accounted within sequences of different HBV subtypes.  

<table>
<thead>
<tr>
<th>Sequence</th>
<th>Position</th>
<th>Expected size of target sequence</th>
</tr>
</thead>
</table>

Corp., Arlington Heights, IL). As controls, RNA samples derived from the same PBMC but treated with DNAase and then RNAase A (100 μg/ml, 1 h at 37°C; ribonuclease A, Sigma Chemical Co.) were used. Additional negative controls included water instead of RNA and omission of oligo-dT primer and reverse transcriptase during cDNA synthesis. HBV-specific sequences were amplified using nested PCR and core specific primers.

**Detection of amplified DNA.** Twenty μl aliquots of the products from direct or nested PCR amplifications were analyzed by electrophoresis on a 0.9% agarose gel in the presence of 0.5 μg/ml of EB. DNA bands were visualized by ultraviolet fluorescence. For Southern-blot analysis, the PCR-amplified DNA was transferred by capillary transfer to a nylon membrane (Hybond-N; Amersham Corp.) and hybridized to 32P-labeled HBC INT or AMP INT probe (17). The membranes were exposed to X-ray film (XAR; Eastman Kodak Co., Rochester, NY) with an intensifying screen.

**Results**

**HBV DNA in Sera of individuals convalescent from acute hepatitis B.** HBsAg was detected in sera obtained during the acute phase of SL-AH in all individuals studied, but not in the samples collected following resolution of the disease (Table I). All but two of the acute phase sera and all of the convalescent phase sera were negative for HBV DNA by slot-blot hybridization (sensitivity ~ 10^3 genome equivalents/ml). The same sera, examined by nested PCR using the HBV core primers and detection of PCR products by EB-agarose or Southern-blot hybridization (sensitivity 10^2 and between 10^4 and 10^5 genome equivalents/ml, respectively), revealed the persistent presence of HBV DNA long after recovery in all individuals studied, except in a patient with fulminating hepatitis (case 5) in whom the only detectable markers of HBV infection at the time of clinical presentation were antibodies to HBs, HBe, and HBc antigens (Table I, legend). It is noteworthy that HBV DNA was detected at intervals as long as 7, 43, 50, and 70 mo after resolution of all conventional parameters of disease in the patients whose sera were available for study. Interestingly, HBV DNA coexisted with anti-HBs in three of these cases for as long as 37–67 mo (cases 2, 3, and 4; Table I).

Surprisingly, semiquantitative evaluation of HBV DNA using serial dilutions of the serum-derived DNA revealed that the level of viral DNA did not decrease dramatically between the earliest and the last samples (Fig. 1). In fact, concentrations of serum HBV DNA remained apparently unchanged in one individual after 7 mo of follow-up (about 10^4 genome equivalents/ml; case 1), whereas the remaining three patients decreased 10–100-fold during a mean observation interval of 55.3 mo (cases 2, 3, and 4) at which time the serum contained between 10^2 and 10^3 genome equivalents/ml.

The possibility that the sera were contaminated by exogenous PCR products or exogenous plasmid DNA was excluded by the inclusion of negative control sera and contamination controls in all assays and by the failure of HBV DNA positive samples to react with primers specific for the pBR322 AMP* gene by nested PCR and Southern-blot hybridization (data not

**Hepatitis B Virus Persistence after Recovery from Acute Viral Hepatitis**

233
shown). Furthermore, amplification with pre-S region primers of the DNA isolated from sera harvested at the end of the follow-up period in cases 1–4 and the HBV plasmids present in our laboratory (ayw subtype), produced DNA fragments of 587 and 554 bp, respectively (data not shown). Size differences between the HBV DNA fragments amplified from the sera and those from the plasmids further eliminated the possibility of false positive results due to plasmid contamination, confirming the validity of the HBV DNA identification in convalescent sera. In addition, the analysis suggested that these patients were most likely infected with the adw subtype of HBV which is the most common subtype in North America (18).

Nested PCR with HBV core specific primers and Southern-blot analysis of DNAs isolated from serum and plasma obtained at the same time point from an HBV-infected patient revealed that heparinization of blood interferes with the subsequent detection of HBV DNA by the PCR procedure described herein, while anticoagulation with EDTA or ACD does not (Fig. 2). This observation has been confirmed using wood-chuck hepatitis virus DNA positive serum and plasma (19).

**Biochemical and biophysical characterization of HBV DNA-positive particles.** To determine if the HBV DNA might be present within intact virions, acute and convalescent serum samples were subjected to sequential DNase and proteinase K digestion before isolation of DNA. Extensive DNase treatment of the samples did not abolish HBV DNA reactivity in any of the sera, but some of the digested samples gave a distinctly weaker hybridization signal (Fig. 3 A). The same treatment of plasmid DNA completely eliminated HBV DNA reactivity, as determined by Southern-blot hybridization of PCR products (Fig. 3 A). DNase resistant HBV DNA displayed DNase sensitivity following digestion with proteinase K (Fig. 3 B), suggesting that the HBV DNA was encased within a protective layer of protein as would occur in a virus particle.

To investigate whether the HBV DNA–protein complexes displayed physicochemical characteristics of circulating virions, late convalescent serum samples from cases 2, 3, and 4 were centrifuged through 15% sucrose in parallel with purified Dane particles and recombinant HBV DNA, and the resulting fractions were tested for HBV DNA and HBsAg. In all three convalescent sera the HBV DNA sedimented to fractions 2 to 5 compared with fractions 2 and 3 for the purified Dane particles (Fig. 4). In contrast, the peak of free HBV DNA reactivity originating from plasmid DNA was detected in fractions 8–11. In view of the prolonged storage of most of the samples, these results are compatible with the presence of partially denatured virions, which would also explain the partial DNase sensitivity of the samples as illustrated in Fig. 3.

**Figure 1.** Quantitation of HBV DNA in serum samples obtained during the acute episode and at the end of follow-up from individuals convalescent from acute hepatitis B. 10-fold dilutions of DNA isolated from the equivalent of 100 μl of serum were amplified by direct PCR with HBV core region primers and products identified by Southern-blot hybridization to HBC INT probe.

**Figure 2.** Effect of anticoagulants on the detection of HBV DNA by PCR. DNA isolated from the equivalent of 25 μl of serum (lane 1) or 25 μl of plasma obtained from heparinized blood (lanes 2 and 3) or blood treated with EDTA (lane 4) or ACD (lane 5) from the same HBsAg-positive patient were amplified by direct (lanes 1, 2 and 4, 5) or nested (lane J) PCR with HBV core specific primers. Viral DNA was detected by Southern-blot hybridization to HBC INT probe.
These observations suggest that the HBV DNA detectable in late convalescent sera is probably present in a particle that displays the sedimentation velocity of virions and co-sediments with HBsAg. Since these sera are positive for anti-HBs, it is possible that the HBV DNA is present within circulating immune complexes.

The late convalescent sera were also subjected to cesium chloride isopycnic density gradient centrifugation in parallel with HBsAg-positive serum from two patients with chronic hepatitis, and purified HBV plasmid DNA (Fig. 5). PCR analysis demonstrated that serum HBV DNA banded at a mean density of 1.36 g/cm\(^3\) in three of the four patients tested. In the remaining patient (case 3) and in two controls chronically infected with HBV, viral DNA banded at a mean density of 1.20 g/cm\(^3\). In contrast, the peak density of recombinant HBV DNA digested with Sau3AI, used as a source of protein-free virus DNA molecules, was found in fractions with a mean density of 1.72 g/cm\(^3\).

**HBV DNA and RNA in PBMC.** Nested PCR amplification with HBV core primers and subsequent Southern-blot hybridization demonstrated the expected 554-bp fragment of HBV DNA in all examined PBMC samples collected from four patients convalescent from acute infection (Fig. 6). Two of these individuals (cases 2 and 4) had detectable HBV DNA in PBMC obtained at 36 and 70 mo of follow-up, respectively. In one patient (case 4), the HBV DNA was detected in three consecutive samples collected at 6, 32, and 70 mo. Hybridization signals displayed by the DNA derived from comparable numbers of PBMC from these samples were approximately of the same intensity. Amplification of DNA isolated from PBMC of the control patient chronically infected with HBV produced HBV DNA fragments of the same size as those detected in PBMC of convalescent patients. DNA from PBMC of an uninfected control and an aliquot of the last wash from the PBMC isolation procedure did not contain detectable HBV DNA reactivity except for a single specimen (case 2) where a weak signal of residual HBV DNA reactivity was seen (Fig. 6). Treatment of intact PBMC with DNAase followed by trypsin before DNA isolation had no effect on the HBV DNA signal in PBMC (data not shown).

Specific HBV RNA sequences were detected by RT-PCR analysis in two PBMC preparations obtained at 39 and 70 mo from cases 2 and 4, respectively. Hybridization signals were detected after pretreatment of the RNA extracts with DNAase and RNAase H excluding the possibility of contamination with viral DNA and DNA/RNA hybrids. No amplification products were obtained when the same RNA samples were pre-treated with DNAase and then with RNAase A or when oligo-dT primers or reverse transcriptase were omitted during cDNA synthesis (Fig. 7).

**Discussion**

This study demonstrates that HBV DNA can persist in the serum and remain transcriptionally active in PBMC for several years after complete serological and clinical resolution of acute viral hepatitis. It corroborates previous reports of persistent HBV DNA sequences in the liver of a single patient with a history of apparently transient viral hepatitis (3), in the liver of a chimpanzee following recovery from acute viral hepatitis due to HBV (20), and in the liver and PBMC in woodchucks conva-
Figure 4. Sedimentation velocity of HBV DNA and HBsAg in sucrose. Sera of individuals convalescent from acute hepatitis B, purified Dane particle preparations, HBsAg-positive serum from a patient with chronic active hepatitis B (CAHB), and recombinant HBV DNA were centrifuged through 4 ml of 15% sucrose onto a 60% sucrose cushion at 40,000 rpm in an SW60 rotor for 4 h at 5°C and 330-µl fractions collected from the bottom. HBV DNA reactivity was determined by direct (D) or nested (N) PCR amplification with HBV core primers in EB-agarose (solid bars) and positiveness of HBsAg tested by Ausria II (Abbott Laboratories) (hatched bars).

Figure 5. Isopycnic banding of serum HBV DNA in individuals convalescent from acute hepatitis B and from control sera and recombinant HBV DNA in cesium chloride density gradients. Sample was centrifuged through a 1.1–1.7 g/cm³ gradient at 40,000 rpm in an SW60 rotor, for 16 h at 5°C, and 330-µl fractions collected from the bottom. HBV DNA reactivity determined using nested PCR amplification with HBV core primers in EB-agarose (solid bars) or location of the peak reactivity using dilutions of the PCR product (hatched bars). On the right side of the figure, location of the approximate peak densities previously reported for the purified Dane particles and core HBV DNA-positive particles (24) and free HBV DNA in the gradient is displayed.
lescent from acute hepatitis due to WHV (6). These results are also consistent with reports that HBV DNA can persist in the serum after spontaneous or therapeutically induced clearance of HBsAg in patients and woodchucks with chronic hepatitis virus infection (4-11, 21, 22). The current report also demonstrates that the viral DNA appears to be packaged within virus-like particles and it suggests that it may exist within viral particles in the context of immune complexes in the anti-HBs-positive sera.

In the present study, the levels of serum DNA showed a tendency to decline over time, but the rate of decrease was very slow. This finding raises the possibility that persistence of HBV DNA after an uncomplicated episode of SL-AH may extend much beyond the time-frame examined in our study. The only patient in our study group whose serum samples were negative during convalescence had fulminant hepatitis B and displayed early anti-HBs, anti-HBe, and anti-HBc IgM responses (case 5). This may suggest that complete virus clearance can occur in acute HBV infection in the context of an exceptionally strong antiviral immune response.

Biochemical analysis of the HBV DNA sequences derived from sera obtained at the end of follow-up of individuals convalescent from acute hepatitis B showed that in all four cases a fraction of the DNA molecules was resistant to extensive DNAase treatment unless the serum was first digested with proteinase K. This property was comparable to that observed in HBV DNA positive sera collected during the acute disease from the same individuals and in a control HBV DNA-positive serum derived from a patient with CAHB. This implies that the DNAase resistant HBV DNA molecules are protected by protein and might suggest the presence of circulating intact viral particles. Ultracentrifugation of the HBV DNA-positive convalescent sera indicated that the DNA migrated with a sedimentation velocity similar to that of purified Dane particles in all three individuals examined. Surprisingly, we were also able to detect HBsAg reactivity (albeit in trace amounts) in sucrose fractions of two of the sera, despite the fact that the unfractinated sera were HBsAg non-reactive and contained anti-HBs-specific antibodies. This is could be interpreted as direct evidence that HBV envelope proteins, not only viral DNA, are persistently produced in anti-HBs-positive patients convalescent from acute hepatitis B, suggesting that the viral genome is transcriptionally and translationally active long after clinical, serological, and biochemical recovery from this infection. This is also consistent with the possibility that HBV DNA-positive viral particles are present in these patients probably within immune complexes. The presence of HBsAg in apparently HBsAg-negative, anti-HBs-positive sera has been previously described, using an assay employing high-affinity monoclonal antibodies to HBsAg (23).

Further analysis of the biophysical properties of the HBV DNA present in the late convalescent sera from 3 of the 4 patients, using isopyknic cesium chloride density gradients revealed that it banded at a mean density of 1.36 g/cm³, which is comparable with the density of dense HBV core particles (24). In the remaining patient (case 3), and in two chronically infected controls, the HBV DNA banded at a mean density of 1.20 g/cm³, which is compatible with the density of intact Dane particles (24). Since the serum HBV DNA from the same patient co-migrated in sucrose gradients with HBsAg (Fig. 4), it would appear that the DNA is packaged within native virus-like particles, at least in this case. In view of the partial DNAase sensitivity of the HBV DNA present in some of these sera, it is possible that the high density HBV DNA actually reflects the presence of viral particles that may have been damaged during prolonged storage. Obviously, further studies will be required to establish the precise nature of the HBV DNA containing particles in these convalescent sera, to deter-
mine if they are infectious and if they contribute to sustained immunity to HBV in this patient population.

At this point, it is important to emphasize that heparin exerts a dramatic inhibitory effect on the subsequent detection of HBV DNA by PCR. This could influence profoundly the outcome of such studies, and it suggests that previously published data should be reassessed if heparinized plasma was used as a starting point for isolation of HBV DNA for subsequent analysis by PCR. This finding corroborates observations that heparin interferes with the PCR assays for detection of human immunodeficiency virus and hepatitis C virus genomes in heparinized plasma (25, 26).

The rate of HBV DNA persistence among patients in our study group is high (80%). In a recent study, Wang et al. (27) tested plasma samples from 206 HBsAg-negative patients, the majority with serologically documented prior HBV infection, for HBV DNA by direct PCR. Only 4% of the patients proved to be positive for HBV DNA in that study. The discrepancy between our results and theirs could be due to sample size, or it might reflect our use of serum instead of anticoagulated plasma, as well as differences the sensitivity between nested and direct PCR assays, and in the interval between onset of infection and the collection of the tested samples (not defined by Wang et al. [27]). Obviously, additional studies will be required to clarify the true incidence of persistent HBV infection after resolution of liver disease, as well as duration of persistence.

Our findings also clearly demonstrate the prolonged persistence of HBV DNA in PBMC after resolution of acute hepatitis B in all four cases studied. Further, we demonstrated the presence of HBV RNA in PBMC collected from two of these patients after more than 3 or 5 years of follow-up. These results suggest that HBV transcription can occur in human PBMC in the context of serological immunity to HBV, years after resolution of hepatitis.

Identification of HBV specific RNA in the PBMC of our patients is consistent with previous reports that hepadnavirus RNA, DNA and protein are detectable in human and woodchuck PBMC even in the absence of serologic evidence of ongoing virus infection (11, 13, 16, 28–36). Since infectious WHV is produced by mitogen-stimulated PBMC from chronically infected woodchucks (37, 38) it is possible that these human cells may also be able to support HBV replication and, thus, serve as a reservoir for cell-to-cell transmission of the virus despite the presence of neutralizing anti-HBs.

Finally, these observations may also have important epidemiological and pathogenetic implications, especially if the HBV DNA-containing particles prove to be infectious, and if viral persistence in PBMC reflects its persistence in the liver or elsewhere in these patients, where it might contribute to the development of chronic diseases that are currently not known to be caused by HBV.

Acknowledgments

The authors thank Dr. John L. Gerin (Georgetown University, Rockville, MD) for providing preparations of purified Dane particles.

This work was supported by U.S. Public Health Service grants AI-20001 and RR-00833. T. I. Michalak was a recipient of a Visiting Scientist Award from the Medical Research Council of Canada and supported in part by the Medical Research Council of Canada research grant MT-11262.

References


